MicroRNA-181 as a prognostic biomarker for survival in acute myeloid leukemia: a meta-analysis
Metrics: PDF 782 views | HTML 1311 views | ?
Qiang Guo1, Junwen Luan1, Ni Li2, Zhen Zhang1, Xiaoxiao Zhu1, Lin Zhao1, Ran Wei1, Linlin Sun1,3, Yin Shi1,3, Xunqiang Yin1,3, Na Ding4, Guosheng Jiang1 and Xia Li1
1Laboratory for TCM Immunology and Epigenetics, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan 250062, Shandong, China
2Muping Hospital of Traditional Chinese Medicine, Yantai 264100, Shandong, China
3School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan 250062, Shandong, China
4Shandong Institute of Scientific and Technical Information, Jinan 250101, Shandong, China
Xia Li, email: email@example.com
Keywords: acute myeloid leukemia, biomarker, microRNA-181, overall survival, prognosis
Received: May 27, 2017 Accepted: June 28, 2017 Published: July 12, 2017
Accumulating evidence has indicated that microRNA-181 (miR-181) is dysregulated in hematological malignancies, and associates with the clinical outcomes. However, the association of miR-181 expression levels with acute myeloid leukemia (AML) remains inconclusive, as publications from different groups have reported contradictory results. In this manuscript, a meta-analysis was performed to assess the prognostic significance of miR-181 in AML patients. Eligible studies were retrieved from PubMed, Embase and Cochrane Library databases, and a total of 6 studies including 815 AML patients were included in the final analysis. Hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were extracted and pooled to investigate the correlation between miR-181 and the survival of AML patients. Our results showed that elevated miR-181 expression was associated with increased survival in 395 American patients, and reduced survival in 325 Chinese patients. Both subgroup analyses and meta-regression indicated that the origin of AML patients contributed to the heterogeneity in the datasets evaluating the correlation between overall survival (OS) and miR-181. These results indicate that miR-181 can be used as a promising prognostic biomarker in AML patients, which may depend on the origin of patient population.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.